Phase II NSCLC Trial To Use Median's Imaging Services
MEDIAN Technologies announced that it has signed a contract with a San Francisco-area based biotech company
MEDIAN Technologies, a medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced that it has signed a contract with a San Francisco-area based biotech company to provide imaging services to support a phase II clinical trial for advanced non-small cell lung cancer.
The study is anticipating imaging data from 90 clinical sites, based in 12 European countries, in the US, and in Canada. Anticipated total enrollment is 440 patients with a "first patient in" forecasted May 2014. Median will supply a set of services including clinical site qualification and training, as well as image and data collection, quality control, and storage.
Read the full release here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.
